ACADIA (NASDAQ: ACAD) director receives RSUs and $21.66 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
ACADIA PHARMACEUTICALS INC director Laura Brege reported equity compensation and option activity. She exercised 8,107 previously granted restricted stock units into 8,107 shares of common stock, bringing her direct common stock holdings to 23,202 shares.
On the same date, she received a new grant of 9,311 restricted stock units, each representing a right to one share of common stock, and a grant of 16,004 director stock options with an exercise price of $21.66 per share, expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units will vest in full on the earlier of one year after grant or the next annual stockholder meeting. Brege has elected to defer receipt of the shares underlying the new restricted stock units until specified future events such as a set anniversary date, ceasing board service, or a change in control under the company’s 2024 Equity Incentive Plan.
Positive
- None.
Negative
- None.
Insider Trade Summary
8,107 shares exercised/converted
Mixed
4 txns
Insider
Brege Laura
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Units | 8,107 | $0.00 | -- |
| Grant/Award | Director Stock Options (Right to Buy) | 16,004 | $0.00 | -- |
| Grant/Award | Restricted Stock Units | 9,311 | $0.00 | -- |
| Exercise | Common Stock | 8,107 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Units — 0 shares (Direct, null);
Director Stock Options (Right to Buy) — 16,004 shares (Direct, null);
Common Stock — 23,202 shares (Direct, null)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
Key Figures
RSUs exercised into common stock: 8,107 shares
Common stock held after transactions: 23,202 shares
New restricted stock unit grant: 9,311 RSUs
+3 more
6 metrics
RSUs exercised into common stock
8,107 shares
Restricted stock units converted to common stock on May 29, 2026
Common stock held after transactions
23,202 shares
Direct holdings following RSU exercise
New restricted stock unit grant
9,311 RSUs
Each unit represents a right to one common share
New director stock options granted
16,004 options
Options on common stock granted on May 29, 2026
Option exercise price
$21.66 per share
Strike price for 16,004 director stock options
Option expiration date
May 28, 2036
Expiration for granted director stock options
Key Terms
Restricted Stock Units, Director Stock Options (Right to Buy), change in control, 2024 Equity Incentive Plan
4 terms
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Director Stock Options (Right to Buy) financial
"The shares subject to each stock option will vest quarterly over one year following the date of grant."
change in control financial
"and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2024 Equity Incentive Plan financial
"as defined in the Issuer's 2024 Equity Incentive Plan, as amended."
FAQ
What insider transactions did ACAD (ACADIA PHARMACEUTICALS) director Laura Brege report?
Laura Brege reported exercising 8,107 restricted stock units into common shares and receiving grants of 9,311 new restricted stock units and 16,004 director stock options. These are compensation-related equity awards, not open-market share purchases or sales.
What are the terms of Laura Brege’s new ACAD director stock options?
Brege received 16,004 director stock options with a $21.66 exercise price per share, expiring May 28, 2036. The options vest quarterly over one year following the grant date, with the final tranche vesting by the earlier of one year or the next annual stockholder meeting.
How do the new restricted stock units for ACAD director Laura Brege vest?
The 9,311 restricted stock units will vest in full on the earlier of one year after the grant date or the next annual meeting of stockholders. Each unit represents a contingent right to receive one ACAD common share upon settlement, subject to the vesting schedule.